Edwards Lifesciences Corporation [NYSE: EW] gained 0.67% or 0.52 points to close at $78.21 with a heavy trading volume of 2360360 shares. The company report on January 24, 2023 that EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2022 after the market closes on Tuesday, January 31, 2023, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.
It opened the trading session at $78.50, the shares rose to $78.55 and dropped to $77.29, the range by which the price of stock traded the whole day. The daily chart for EW points out that the company has recorded -25.94% loss over the past six months. However, it is still -16.51% lower than its most recent low trading price.
If we look at the average trading volume of 5.17M shares, EW reached to a volume of 2360360 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Edwards Lifesciences Corporation [EW]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $91.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Edwards Lifesciences Corporation shares, keeping their opinion on the stock as Hold, with their previous recommendation back on December 06, 2022. The new note on the price target was released on October 28, 2022, representing the official price target for Edwards Lifesciences Corporation stock. Previously, the target price had yet another raise to $100, while Mizuho analysts kept a Buy rating on EW stock.
The Average True Range (ATR) for Edwards Lifesciences Corporation is set at 1.89, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 8.92. The Price to Book ratio for the last quarter was 7.80, with the Price to Cash per share for the same quarter was set at 2.84. Price to Free Cash Flow for EW in the course of the last twelve months was 45.86 with Quick ratio for the last quarter at 3.00.
Trading performance analysis for EW stock
Edwards Lifesciences Corporation [EW] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.33. With this latest performance, EW shares gained by 5.42% in over the last four-week period, additionally sinking by -25.94% over the last 6 months – not to mention a drop of -28.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 55.39, with the RSI for the last a single of trading hit 55.07, and the three-weeks RSI is set at 53.82 for Edwards Lifesciences Corporation [EW]. The present Moving Average for the last 50 days of trading for this stock 75.59, while it was recorded at 78.47 for the last single week of trading, and 90.09 for the last 200 days.
Edwards Lifesciences Corporation [EW]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Edwards Lifesciences Corporation [EW] shares currently have an operating margin of +30.78 and a Gross Margin at +76.57. Edwards Lifesciences Corporation’s Net Margin is presently recorded at +28.73.
Return on Equity for this stock inclined to 28.88, with Return on Assets sitting at 19.10.
Edwards Lifesciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.00 and a Current Ratio set at 3.80.
Edwards Lifesciences Corporation [EW]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corporation go to 11.05%.
An analysis of insider ownership at Edwards Lifesciences Corporation [EW]
There are presently around $39,092 million, or 84.90% of EW stock, in the hands of institutional investors. The top three institutional holders of EW stocks are: BLACKROCK INC. with ownership of 52,402,436, which is approximately -5.989% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 50,911,104 shares of the stock with an approximate value of $3.98 billion in EW stocks shares; and STATE STREET CORP, currently with $2.1 billion in EW stock with ownership of nearly -0.338% of the company’s market capitalization.
Positions in Edwards Lifesciences Corporation stocks held by institutional investors increased at the end of January and at the time of the January reporting period, where 564 institutional holders increased their position in Edwards Lifesciences Corporation [NYSE:EW] by around 27,017,695 shares. Additionally, 571 investors decreased positions by around 29,363,708 shares, while 226 investors held positions by with 443,457,433 shares. The mentioned changes placed institutional holdings at 499,838,836 shares, according to the latest SEC report filing. EW stock had 109 new institutional investments in for a total of 6,150,826 shares, while 119 institutional investors sold positions of 2,598,929 shares during the same period.